South Australian researchers working with Oracle Cloud technology and vaccine technology developed by local company Vaxine Pty Ltd are testing a vaccine candidate against the SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic.
The team is headed by Nikolai Petrovsky, Flinders University Professor and Research Director at Vaxine.
His team has tapped Oracle for technical collaboration, access to an expanded research community, and cloud infrastructure that helped enable the rapid design of the novel COVID-19 vaccine candidate.
“The vaccine has progressed into animal testing in the US and, once we confirm it is safe and effective, will then be advanced into human trials,” says Professor Petrovsky – stressing expectations shouldn’t be elevated until all testing is completed.
The latest cloud-based technology provided by Oracle enabled the team to “dramatically speed up our ability to analyse the COVID-19 virus and use this information to design the vaccine candidate”.
“As soon as the genomic sequence of COVID-19 became available in January, we immediately used this, combined with our previous experience in developing a SARS coronavirus vaccine, to characterise the key viral attachment molecule called the spike protein,” Professor Petrovsky says.
“We used computer models of the spike protein and its human receptor, ACE2, to identify how the virus was infecting human cells, and then were able to design a vaccine to block this process,” he says.
Flinders University Associate Professor Dimitar Sajkov, a respiratory physician in South Australia, has been involved in conducting previous human trials of the team’s pandemic vaccines and hopes to similarly lead clinical trials of this new COVID-19 vaccine candidate.
“The team has exploited the very latest technologies, including AI, advanced manufacturing and Cloud computing to accelerate vaccine design, shaving years off normal development timeframes,” Professor Sajkov says.
“We achieved great results with Vaxine’s swine flu vaccine developed during the 2009 swine flu pandemic, where we commenced clinical trials of a vaccine within 3 months of discovery of the virus. We hope to achieve similar results with their COVID-19 vaccine candidate when it is ready for human testing,” he says.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
COVID-19 vaccine
- University of Florida Health COVID-19 guide offers vaccine finder and shares community vaccination stories
University of Florida Health website features vaccine availability by county, community champion stories, and resources.
- Children who suffered complications after COVID will not see recurrence after vaccine, study says
The COVID-19 vaccine does not cause any additional side effects for children who developed MIS-C, or multisystem inflammatory syndrome, a study co-authored by a Utah doctor found. The study was ...
- Have More Athletes Really Died Suddenly Since Covid-19 Vaccines Arrived?
FOX News host Tucker Carlson has claimed on his show, “Since the vax campaign began, there have been more than 1,500 total cardiac arrests in those leagues and two-thirds of those were fatal.” ...
- New York eyes nixed COVID-19 vaccine rule for health workers
The New York State Department of Health is “exploring its options” after a state Supreme Court judge struck down a statewide mandate requiring health care workers to be vaccinated against COVID-19, ...
- COVID-19 Vaccine Hesitancy Linked to Increased Risk of Traffic Accidents
New research suggests that individuals who disregard recommendations for vaccination against coronaviruses may also disregard rules of road safety. A new study published in The American Journal of Med ...
Go deeper with Google Headlines on:
COVID-19 vaccine
[google_news title=”” keyword=”COVID-19 vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
COVID-19 treatment
- COVID-19: World cases decline 23%, deaths 13% excluding mainland China
COVID-19 is easing worldwide with a weekly 23% decrease in cases and 13% drop in deaths with one big qualifier: excluding mainland China where the virus emerged three years ago.
- Study shows convalescent plasma works for immune-compromised COVID-19 patients, but it can be hard to find
The report in the journal JAMA Network Open analyzed the results of nine studies and found that immune-compromised COVID-19 patients were 37% less likely to die if they got convalescent plasma, an ...
- Study shows convalescent plasma works for immune-compromised Covid-19 patients, but it can be hard to find
Convalescent plasma – a once-celebrated treatment for Covid-19 that has largely fallen out of favor – does work well for people who are immune-compromised, according to a study published Thursday.
- How COVID-19 Impacting Silicone Scar Treatment Products Market [Up-to-date Report] Size Globally 2023-2028? | [128 Pages Report]
Pre and Post Covid Report Is Covered | Final Report Will Add the Analysis of the Impact of Russia-Ukraine War and ...
- In Hamlin’s medical treatment and COVID-19 realities, contradictions in the US medical system in full view
Our sophisticated emergency treatment is unrivaled even as the comprehensive U.S. patient care system remains the world’s most expensive and possibly the most dysfunctional.
Go deeper with Google Headlines on:
COVID-19 treatment
[google_news title=”” keyword=”COVID-19 treatment” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
